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Structures of the Cancer-Related
Aurora-A, FAK, and EphA2 Protein
Kinases from Nanovolume Crystallography
known as eck) [5] preferentially binds the GPI-anchored
ligand ephrin-A1 (previously known as B61) [6, 7]. The
overexpression of EphA2 has been observed in a variety
of malignant carcinomas, including breast cancer [8–10],
prostate cancer [11], and melanoma [12, 13]. Recently,
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may play a role in malignant progression through tumor
neovascularization [8]. In vivo and in vitro evidence sug-
gests that overexpression of EphA2 has the ability toSummary
confer tumorigenic potential [9]. Thus, the inhibition of
EphA2 activity may provide therapeutic value throughProtein kinases are important drug targets in human
the disruption of angiogenesis in tumor proliferation andcancers, inflammation, and metabolic diseases. This
invasion.report presents the structures of kinase domains for
A number of studies have suggested that activationthree cancer-associated protein kinases: ephrin re-
of EphA2 negatively regulates cell-extracellular matrixceptor A2 (EphA2), focal adhesion kinase (FAK), and
adhesions and cell growth, by a mechanism that ap-Aurora-A. The expression profiles of EphA2, FAK, and
pears to involve suppression of the focal adhesion ki-Aurora-A in carcinomas suggest that inhibitors of
nase (FAK) [9, 14, 15], although a recent study reportsthese kinases may have inherent potential as thera-
contrary findings, indicating that ephrin-A-EphA2 signal-peutic agents. The structures were determined from
ing promotes FAK- and p130cas-dependent cell adhe-crystals grown in nanovolume droplets, which pro-
sion and cytoskeletal assembly [16]. FAK is a nonrecep-duced high-resolution diffraction data at 1.7, 1.9, and
tor tyrosine kinase that is involved in signal transduction2.3 A˚ for FAK, Aurora-A, and EphA2, respectively. The
pathways thought to be important in tumor invasionFAK and Aurora-A structures are the first determined
and metastasis, including cell adhesion, migration, andwithin two unique subfamilies of human kinases, and
anchorage-independent growth [17, 18]. FAK is acti-all three structures provide new insights into kinase
vated through phosphorylation by the integrin family ofregulation and the design of selective inhibitors.
cell-surface receptors that mediates attachment of cells
to the ECM and utilizes the scaffold protein paxillin [19,
Introduction 20]. Evidence is emerging that indicates a signaling part-
nership between FAK and the Src family of protein ki-
Human protein kinases are attractive targets for the de- nases that involves the recruitment of docking proteins
velopment of new therapeutics because of their involve- and proteins containing SH2 domains [21]. It has been
ment in processes associated with the progression of demonstrated that FAK is overexpressed in metastatic
cancers and metabolic diseases [1, 2]. Because of the colon, metastatic breast, and thyroid tumors and that
size of the kinase family, which is believed to include the levels of protein expression correlate with the inva-
approximately 500 identified members to date [3], signif- sive potential of the tumor [17]. In addition, an abun-
icantly more structural information pertaining to individ- dance of FAK protein has been observed in human mela-
ual kinases is required in order to guide structure-based noma cell lines, where it appears to be required for
inhibitor design efforts. In this report we present three substrate adhesion [22]. The attenuation of FAK in can-
novel structures of cancer related kinases, ephrin recep- cer cell lines results in an inhibition of cell attachment,
tor A2 (EphA2), focal adhesion kinase (FAK), and Au- leading to apoptosis, and suggests a role for FAK in
rora-A, representing three separate classes of human adhesion-mediated tumor growth [23]. FAK is overex-
protein kinases: receptor tyrosine kinase, nonreceptor pressed in vascular smooth muscle cells during the pro-
tyrosine kinase, and serine/threonine kinase, respec- cess of intimal hyperplasia, implicating FAK in migration
tively. and proliferation events [24].
The Eph family comprises the largest subfamily of Although many RTKs have been implicated in tumori-
RTKs, with 14 identified members. Eph receptors have genesis, considerably fewer serine/threonine kinases
been most-extensively studied during developmental (STKs) have been shown to be involved in oncogenic
processes and have been implicated in cell migration, processes. Aurora-A represents a cell cycle-regulated
axon guidance, and the formation of embryonic vascula- [25] STK that has been correlated with oncogenic poten-
ture [4]. The ligands for Eph receptors are a family of tial through gain in kinase activity [26, 27]. Aurora-A
eight membrane bound ephrins. EphA2 (previously
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(synonyms include Aurora2, Aik, BTAK, STK15, ARK1,
and HsAIRK1; see [28]) was identified as a novel colon
cancer-associated kinase that is overexpressed in more
than 50% of primary colorectal cancers [27]. Aurora-A
is a member of the Aurora/Ipl1p family that regulates
centrosome maturation, chromosome segregation, and
cytokinesis, ensuring genetic integrity of progenic cells
[29]. In addition to colon cancer, Aurora-A amplification
and overexpression have been detected in breast tu-
mors [30, 31], ovarian tumors [32], and multiple tumor
cell lines, including breast, ovarian, colon, prostate, neu-
roblastoma, and cervical [30, 32, 33]. Evidence is mount-
ing to suggest that Aurora-A may play a role in onco-
genic transformation [26, 27, 30] and that this may be
mediated through centrosome amplification, resulting
in chromosomal instability [34]. A cell cycle-dependent
feedback of phosphorylation/dephosphorylation events
between Aurora-A and protein phosphatase type 1 (PP1)
has been described during the mitotic cell division cycle,
for the regulation of Aurora-A kinase activity [35]. Dereg-
ulation of the phosphorylation/dephosphorylation bal-
Figure 1. Images of the Nanovolume Crystallization Droplets andance in signaling pathways is believed to contribute
Microcrystals Used for Protein Structure Determination
significantly to oncogenic processes.
(A) Fragment of the crystallization plate showing the size of a 50 nlTo gain insight into the structural diversity of the hu-
droplet (white arrow) and the actual crystals of (B) FAK, (C) Au-
man protein kinase family and to facilitate structure- rora-A, and (D) EphA2 used to collect the X-ray diffraction data. dmin
based inhibitor design, we have determined the crystal indicates the resolution of the data collected from each crystal.
structures of EphA2, FAK, and Aurora-A catalytic do-
mains at 2.3, 1.7, and 1.9 A˚. The structures were deter-
kinase catalytic domains (Figures 2 and 3) [38]. Themined by novel nanovolume crystallography tech-
smaller N-terminal lobes contain a five-stranded antipar-niques, resulting in significant savings of time and
allel  sheet and a single  helix (C), except Aurora-A,sample as compared with the conventional crystalliza-
which has an additional helix preceding C. The largertion approaches.
C-terminal lobes are mostly  helical and contain the
activation loop involved in polypeptide substrate bind-Results and Discussion
ing. The nucleotide ligands that were cocrystallized with
the kinase domains (ATP with FAK, AMP-PNP withStructure Determination
EphA2, and ATPS with Aurora-A) bind in a cleft betweenA combination of highly parallel protein expression, puri-
the two lobes. The three kinase structures show consid-fication, and crystallization techniques [36, 37] was used
erable variability in the relative orientation of the N andto obtain crystals of EphA2, Aurora-A, and FAK kinase
C lobes, in the position and orientation of the C, anddomains. In this approach, the kinase catalytic domains
in the conformation of the activation loop. This confor-were expressed in insect cells as a series of molecular
mational variability has been observed with other kinaseconstructs designed to alter the crystallization proper-
structures, and it has been correlated with the regulationties of the protein. The modifications included alterna-
of the kinase, typically as a result of phosphorylationtive domain boundaries and purification tags. The puri-
and/or regulatory protein binding [38, 39].fied proteins were screened for their propensity to form
crystals by nanovolume sitting-droplet crystallization
Structure of Aurora-Atechnology (Figure 1). Each crystallization experiment
Of the three kinases, only Aurora-A adopts the activeconsisted of a 50 nl sitting droplet, equilibrated through
conformation, first seen in the structure of the phosphor-vapor diffusion against a 100 l reservoir. The crystals
ylated cAMP-dependent protein kinase (PKA) [40]. Thegrown from nanovolume droplets were small in size
two lobes clamp together, bringing residues of the cata-(100 m), but most were sufficient to produce high-
lytic cleft into alignment (Figures 2A and 3A). The Cresolution diffraction when exposed to a synchrotron
helix is positioned such that the conserved residue E181radiation source (Figure 1 and Table 1). The nanodroplet
makes a salt bridge with K162, in close proximity to thecrystallization approach reduced the sample require-
-phosphate of the bound ADP ligand (Figure 5A). Thements and time for structure determination. Typically,
activation loop (A loop; residues 274–297) is well or-1–3 mg of protein were sufficient to set up over 1200
dered, with the exception of residues 286 and 287. Thecrystallization conditions. The small drop volume accel-
conformation of the A loop allows access to the sub-erated crystal growth, such that crystals typically
strate binding site and is similar to that of the phosphory-reached maximal size within 48 hr.
lated A loop of PKA [40] and cdk2 [41]. The observation
of an active Aurora-A conformation was unanticipated,Overall Structures of the Kinase Domains
since most kinases require phosphorylation of their acti-The overall folds of the three kinases are similar and
exhibit a bilobal architecture that is typical of protein vation loop in order to adopt the active conformation
Structures of Aurora-A, FAK, and EphA2 Kinases
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Table 1. Crystallographic Data and Refinement Statistics
FAK Aurora-A EphA2
Crystal Data
Ligand ATP ATPS AMP-PNP
Space group P21 P6122 P3221
Unit cell dimensions a  45.135, b  46.56, c  62.07,   80.77 a  b  80.45, c  172.18 a  b  72.12, c  241.62
Data Collection
X-ray source ALS Bl 5.0.3 ALS Bl 5.0.3 ALS Bl 5.0.3
Wavelength (A˚) 1.0 1.0 1.0
Resolution (A˚) 46–1.7 44–1.9 63–2.3
Observations, unique 24,650 28,879 35,483
Redundancy 3.8 7.4 4.1
Completeness 91.1% (65%)a 98% (93%) 95% (78%)
I/(I) 16.0 (2.8) 14.5 (1.6) 11.5 (2.0)
Rsymb 0.071 (0.255) 0.086 (0.578) 0.057 (0.485)
Refinement
Reflections used 22,650 25,081 30,484
R factorc 17.9% 22.6% 23.5%
Rfree (5% of reflections) 23.0% 27.2% 28.9%
Rms bonds 0.015 0.013 0.021
Rms angles 1.66 1.468 2.11
a Values in parentheses refer to the highest-resolution shell.
b Rsym  hkli|I(hkl)i 	 I(hkl)
 |/hkliI(hkl)i
 over I observations of a reflection, hkl.
c R factor   |Fobs 	 Fcalc|/Fobs.
[39]. It has been shown that Aurora-A can be phosphory- activated kinases, suggesting that the phosphate-
bound AIK structure mimics a catalytically active confor-lated in vitro by PKA at residue T288, resulting in signifi-
cantly increased activity [42]. Although unphosphory- mation.
GSK3, Chk1, and casein kinase 1 (CK1) have alsolated Aurora-A protein was used in crystallization, there
is a free phosphate ion bound near T288 (the distance been reported to crystallize in the active conformation
with their activation loop bound to phosphate or sulfatebetween the phosphorus atom and O of T288 is 3.7 A˚).
The phosphate is bound in a pocket created by the side ions [43–45]. In the case of GSK3, the phosphate ion
has been suggested to mimic a phosphothreonine resi-chains of R180, H176, and R255. These side chains
are in positions analogous to those in phosphorylated, due of the polypeptide substrate, as one of the two
Figure 2. The Structures of the Kinase Domains Oriented to Show the Relative Positions of the C- and N-Terminal Lobes
(A) Ribbon diagram of the Aurora-A structure.  helices, purple;  sheets, orange; the activation loop (A loop), green; Mg2 ions, yellow spheres;
the bound phosphate, green and red.
(B) FAK structure. The arrow points to the location of the short-range disulphide bond (orange).
(C) EphA2 structure. All ribbon diagrams are color coded according to the secondary structure, and the bound ATP ligands are shown in red.
The figure was prepared with PyMOL (The PyMOL Molecular Graphics System; DeLano Scientific, 2002).
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Figure 3. Stereo Views of the C Traces
Shown in the Same Orientation as in Figure 2
(A) Aurora-A; (B) FAK; (C) EphA2. Every tenth
residue is labeled with a number and marked
with a closed circle. The figure was prepared
with Xfit [56].
classes of GSK3 substrates have to be primed by previ- that have to be primed. Alternatively, the phosphate ion
in the Aurora-A structure may simply mimic the nativeous phosphorylation at the P4 position by other ki-
nase(s) [43]. The best-established substrates of the Au- phosphorylation site.
rora kinase family, histone H3 and the centromeric
protein CENP-A [46, 47], do not seem to have a pattern Structure of Focal Adhesion Kinase
FAK displays an open conformation similar to the struc-of closely spaced phosphorylation sites, and it is not
clear whether Aurora-A has another class of substrates tures of the fibroblast growth factor receptor-1 (FGFR1)
Structures of Aurora-A, FAK, and EphA2 Kinases
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kinase activity through protein-protein interactions [50],
and it is conceivable that the disulphide bond might be
protected upon binding of regulatory proteins.
Structure of Ephrin Receptor A2
The conformation of the EphA2 kinase is similar to the
unphosphorylated, auto-inhibited structure of the mu-
rine EphB2 kinase domain (the rms deviation between
267 C atoms of the two structures is 1.2 A˚) [50]. The
lobes of EphA2 are in the open conformation, and the
activation loop is disordered (Figure 2C). The salt bridge
between the conserved K646 and E663 residues is not
maintained in the structure (Figure 5C), suggesting that
the crystallized protein mimics the inactive form of the
EphA2 kinase. The previously solved structure of the
EphB2 kinase domain suggested a novel mode of au-
toinhibition resulting from the juxtamembrane region in-
teracting with the C helix and kinking it [50]. Surpris-
ingly, despite the absence of the juxtamembrane region
and any crystal packing interactions, the structure of
the human EphA2 displays a similar bent conformation
of the C helix (11 and 14 for EphA2 and EphB2, re-
spectively). This suggests that the C helix in Eph kinase
domains may have evolved an inherent structural flexi-
bility that facilitates autoinhibition.
Comparison of ATP Binding Sites
Figure 4. Short-Range Disulphide Bond in the Focal Adhesion
The ATP binding sites of protein kinases are the mostStructure
common targets for the design of small-molecule inhibi-(A) Close-up view of the N-terminal lobe of the focal adhesion kinase
tors. Historically the development of selective kinaseshowing the structure of the short-range disulphide bond.
inhibitors had been difficult because of the inherent simi-(B) Structure-based sequence alignment of human FAK homologs.
Cysteines 456 and 459, which form the disulphide bond in the FAK larities between kinase domains. However, the exploita-
structure, are highlighted in red. Pyk2 is the second member of the tion of small structural differences between the ATP
human FAK family. binding sites of even closely homologous kinases has
been used successfully to confer specificity of inhibition
[51, 52]. In Aurora-A, the bound ADP interacts with the[48] and the vascular endothelial growth factor receptor
(vEGF) [49]. The C helix is rotated away from the C-ter- protein both directly and through water-mediated con-
tacts (Figure 5A). The adenine base inserts into a hy-minal lobe, and the activation loop is disordered, consis-
tent with a lack of phosphorylation (Figures 2B, 3B, and drophobic pocket formed by the side chains of L210,
Y212, A213, L139, V147, and L263. The N1 nitrogen and4A). Despite the open conformation of the lobes, the
salt bridge between K454 and E471, characteristic of the amino group of the adenine ring hydrogen bond to
the main chain of A213 and E211, respectively. Theseactive kinase structures, is formed in the structure (Fig-
ure 5B). A striking feature of the FAK kinase is the pres- two hydrogen bonds are conserved in all kinase struc-
tures. The active sites of Aurora-A and FAK display aence of an intramolecular disulphide bond in the N-termi-
nal lobe of the kinase (Figures 2B and 4A). The disulphide network of ordered water molecules, which participate
in the hydrogen bonding within the binding site (Figurespans a short turn of four residues between C456 and
C459. This turn closely resembles a type-I  turn, with 5). The structure of Aurora-A contains two Mg2 ions,
which are coordinated directly to the phosphates andresidues n and n 3 covalently linked through the disul-
phide bond. This unusual feature is located on the sur- to the conserved aspartate D274. The overall position
of the bound ATP is similar in all three structures.face of the N-terminal lobe adjacent to the C helix
(Figure 2B). Cysteines 456 and 459 are conserved in The key structural differences in the three ATP sites
are clustered around the ribose ring and the N7 atomvertebrate FAK sequences, suggesting a possible role
in kinase function (Figure 4B). The proximity of the disul- of the adenine base (Figure 5). The area adjacent to N7
has been utilized in the past to confer specificity to somephide to the C helix suggests also that its role may lie
in fine-tuning the orientation of this helix. Disulfide of the most selective kinase inhibitors, including STK-
571 (Gleevec) [53]. This region forms a hydrophobicbonds are extremely rare in cytoplasmic proteins be-
cause of the reducing nature of the intracellular environ- pocket bordered by the residues M499 in FAK, L210 in
Aurora-A, and T692 in EphA2. The size and shape of thement. It is unknown whether the C456-C459 bond
formed in the FAK crystal structure is maintained in pocket varies amongst the three structures. In particular,
T692 in EphA2 forms a hydrogen bond to the aminovivo, especially since this feature is located close to the
protein surface. The corresponding structural region in group of ATP. This interaction is not commonly seen in
other kinases and could provide selectivity against theother kinases has been implicated in the regulation of
Structure
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Figure 5. Stereo Diagrams of the ATP Binding Sites
(A) Aurora-A ATP binding site. Carbon atoms, gray; oxygen atoms, red; nitrogen atoms, blue; phosphorus atoms, green. Water molecules and
Mg2 ions are represented by red and blue crosses, respectively.
(B) FAK ATP binding site
(C) EphA2 ATP binding site. The representative 2Fo 	 Fc electron density around the ATP has been computed at 1.9, 1.6, and 2.3 A˚ for Au-
rora-A, FAK, and EphA2, respectively. The density is contoured at 1  (blue) and 4  (red). The side chains of the residues that distinguish
the structures of the ATP binding sites are shown with the dotted van der Waals surface. Hydrogen bonds between the protein and ATP are
shown as dashed lines. The figure was prepared with Xfit [56].
ephrin receptor kinases (Figure 5C). A second region of Ultimately, the goal of selective inhibition of protein
kinases that are involved in tumor progression and me-significant structural difference is located at the ribose
binding site. In FAK, the side chain of E506 forms a tastases is to provide new therapeutic agents for the
treatment of human cancers. The first FDA-approvedbifurcated hydrogen bond to the 2 and 3 hydroxyl
groups of the ribose. The corresponding side chains of selective tyrosine kinase inhibitor, Gleevec, has been
shown to substantially reduce the level of cancerousT217 in Aurora-A and A699 in EphA2 are smaller and do
not directly contact the sugar (Figure 5). cells in the bone marrow and blood of patients with
Structures of Aurora-A, FAK, and EphA2 Kinases
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The proteins were concentrated to final concentrations of 9.4 mg/chronic myeloid leukemia (CML), through inhibition of
ml for Aurora-A, 6.1 mg/ml for FAK, and 10.7 mg/ml for EphA2. AllBCR-ABL [54]. Subtle differences between protein ki-
samples were stored at 4C in a buffer containing 50 mM Tris-HClnases, as elucidated through structural determination,
(pH 7.6), 250 mM NaCl, 1mM EDTA, and 1 mM DTT. Kinase activity
will undoubtedly be pivotal in the development of selec- was not tested before crystallization for any of the three proteins.
tive kinase inhibitors. The nanovolume crystallography
approach should facilitate a rapid generation of struc- Crystallization and Data Collection
FAK, Aurora-A, and EphaA2 samples were incubated with 2 mMtural data for protein kinases and other protein super-
ATP, ATPS, or AMP-PNP, respectively, and 4 mM MgCl2 beforefamilies and become a powerful tool in structure-based
crystallization trials were set. Crystals were grown in sitting dropletsdrug discovery.
by the vapor diffusion method. A 50 nl droplet of protein was mixed
with an equal volume of reservoir solution and incubated over a
period of one week. The reservoir conditions were as follows: 0.1Biological Implications
M Bicine (pH 9.0), 20% PEG MME 550, and 0.1M NaCl for Aurora-
A; 0.1 M citrate/acetate (pH 5) and 24% PEG MME 2K for FAK; 0.1MFAK, EphA2, and Aurora-A represent three different
HEPES (pH 7.5), 10% PEG 10K, and 8% ethylene glycol for EphA2.
classes of human protein kinases: nonreceptor tyrosine The reservoir volume was 100 l. Crystals typically appeared after
kinase, receptor tyrosine kinase, and serine/threonine 8–24 hr and grew to their final size within 48 hr (Figures 1A–1C). For
kinase, respectively. The crystal structures of these en- data collection at low temperature, the crystals were captured in a
0.05 mm nylon loop (Hampton Research) and transferred briefly intozymes provide insights into the structural diversity of
a cryoprotecting solution containing the reservoir solution supple-protein kinases and shed light on possible modes of
mented with 20% v/v ethylene glycol. The crystals were flash-frozentheir regulation. The Aurora-A structure is in the
by immersion in liquid nitrogen and stored under liquid nitrogen.
“closed,” active conformation, despite the absence of Diffraction data were collected at 100 K on the Advanced Light
activating phosphorylation at T288. Instead, a bound Source beamline 5.0.3 with an ADSC CCD detector. Reflection data
were integrated with MOSFLM and scaled with SCALA [55]. Thephosphate ion organizes the activation loop. The similar-
data collection statistics are given in Table 1.ity of this structure to the phosphate-bound GSK3 ki-
nase structure [43] suggests that Aurora-A might apply
Structure Determination and Refinement
a similar mode of “primed substrate” recognition with All crystallographic calculations were performed with the CCP4 pro-
respect to its substrates. The FAK structure reveals an gram package [55]. The initial phases for each structure were ob-
unusual short-range disulphide bond between the con- tained by the molecular replacement method with the program
AMORE. The coordinates of murine EphB2 kinase domain (Proteinserved residues C456 and C459. The proximity of the
Data Bank code 1JPA) were used as a search model for the solutionsdisulphide to the C helix suggests that it may have a
of the EphA2 (72% identity) and FAK (40% identity) structures. Therole in fine-tuning the orientation of this helix, although
coordinates of yeast cAPK (Protein Data Bank code 1FOT) were
it is unknown whether the disulphide is actually formed used to solve the Aurora-A structure (38% identity). For each struc-
in the highly reducing cellular environment. The struc- ture, the highest solution from the translational function was sub-
jected to a rigid-body rotation and then to refinement against theture of EphA2 reveals a significant kink of the C helix,
maximum-likelihood method, as implemented in REFMAC. Multiplepreviously seen in the structure of murine EphB2 [50].
rounds of manual building with Xfit [56] combined with ARP/wARPIn the EphB2 structure, the distortion of the C helix
map improvement [57] led to the final models. The refined crystalwas caused by the intramolecular binding of the juxta- structure of the unphosphorylated Aurora-A kinase domain contains
membrane region, implying a novel mode of autoinhi- residues 126–388 and a bound ATPS ligand. The crystal structure
bition. Surprisingly, the kink in EphA2 C is present of the unphosphorylated, ATP-bound FAK kinase domain includes
residues 413–686. The majority of the structure is well defined, withdespite the absence of the juxtamembrane region, sug-
the exception of the disordered activation loop (residues 565–583)gesting that the C helix in Eph kinases may have
and a short loop connecting 2 and 3 (residues 445–446) in theevolved an inherent structural flexibility that facilitates
N-terminal domain. The -phosphates of the ATPS and ATP ligands
autoinhibition. in Aurora-A and FAK, respectively, are not visible in the electron
densities and were excluded from the final models. The EphA2 struc-
Experimental Procedures ture contains the kinase domain (residues 602–900) and the AMP-
PNP ligand. Most of the structure is well defined, with the exception
Expression and Purification of residues 596–603 and 734–738 (the loop connecting 2 and 3)
The portions of the genes encoding the catalytic domains of human and the activation loop residues 760–883.
Aurora-A (residues 125–391; GenBank accession number
NP_003591), human EphA2 (residues 596–900; GenBank accession Acknowledgments
number NP_004422), and human FAK (residues 411–686, GenBank
accession number Q05397) were isolated from cDNA libraries (testis, We thank Stella Kim for bacmid generation, Angela Kondrat for DNA
lung/spleen/HeLa, and HeLa, respectively) by PCR and cloned into sequencing analyses, Robert Wynands, Susan Camper, and Bernard
the BamH I site of pFastbacHTb (Gibco-BRL). Expression in this Collins for support in protein purification, Kheng Lim for mass spec-
vector generated fusion of the kinase domain with a cleavable (rTev) trogram analysis, Darbi Witmer for protein biophysical analyses,
N-terminal His6 tag. Recombinant baculoviruses incorporating the Erin Heien for crystallization support, Sheng Ye and Yanming Zhang
kinase cDNA constructs were generated by transposition with the for help in structure solution and refinement, and Bettina Roth for
Bac-to-Bac system (Invitrogen). High-titre viral stocks were gener- bioinformatics support.
ated by infection of Spodoptera frugiperda Sf9 cells, and the expres-
sion of recombinant protein was carried out by infection of Tri- Received: August 14, 2002
choplusia ni Hi5 cells (Invitrogen). Recombinant proteins were Revised: September 19, 2002
isolated from cellular extracts by passage over ProBond (Invitrogen) Accepted: September 20, 2002
resin. Polyhistidine tags were removed by treatment with rTEV prote-
ase (Invitrogen) (the tag on EphA2 was not removed), and the unclea- References
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